4DMedical has delivered a share price gain of 133.5% over the past three years, which naturally puts the focus on whether that kind of run is backed by the cash the business can generate. With the stock now around A$2.16 after some recent weakness, the live issue is how that price lines up with the value suggested by its future cash flows.
The stock's next move may depend on whether those projected cash flows, when run through a Discounted Cash Flow (DCF) lens against the industry average, line up with where 4DMedical trades today.
If you are weighing 4DMedical against other opportunities that hinge on future cash generation, it can help to compare it with 3 high quality undervalued stocks.
The Discounted Cash Flow model here looks at what 4DMedical could produce in future cash terms and then scales that back to today. Over the last twelve months the business reported free cash flow of A$33.36m in outflows, which means the valuation work is leaning heavily on a turn in cash generation rather than current strength.
Analysts and modelled estimates point to free cash flow still in the red in 2027 and 2028, then moving into positive territory by 2029 and rising from there. This is framed as a recovering and then growing cash profile rather than a steady, mature one. Against a share price of A$2.16, the DCF projections put 4DMedical's estimated intrinsic value substantially above the current share price. This only holds if those future cash inflows arrive broadly in line with these expectations and the company can fund the path from current losses to those later A$ cash returns. Find out what 4DMedical could be worth using our Discounted Cash Flow (DCF) estimate.
4DMedical's valuation story raises more questions than it answers. This is where Simply Wall St Narratives come in as a bridge between the cash flow puzzle and the assumptions that would need to hold for the share price to move meaningfully higher or lower. Narratives lay out the moving parts behind 4DMedical's future, from growth and margins to potential earnings power. Instead of a single model output, they spell out the underlying levers so you can compare those expectations with actual results over time on Simply Wall St's Community page.
One of the top community narratives on 4DMedical: 81% undervalued
According to ethanwong, an investor in the Simply Wall St Community, the 4DMedical story hinges on how quickly its lung imaging tech scales in major hospitals.
"Partnership with Philips promised a $10Million USD minimum order commitment contract over the next 2 years starting December 2025, Philips has added 4DMedicals CT:VQ technology as an official product on their catalog in North America…"
Discover why this Narrative puts 4DMedical at 81% undervalued.
Before you focus only on what 4DMedical might be worth, it helps to see where our broader checks have raised questions that could change how you frame the opportunity. Take a closer look at 3 warning signs before settling on a valuation.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com